A critical review of how (we think)
#zuranolone, a treatment for
#postpartumdepression was rushed through the
#FDA, resulting in cut corners that allowed its marketing without much evidence of benefit.
#medsky bpspubs.onlinelibrary.wiley.com/doi/10.1002/...
BPS Publications
Sage, in collaboration with Biogen, submitted a new drug approval for zuranolone for postpartum depression (PPD) and major depressive disorder (MDD) in December 2022. In August 2023, the US Food and ...
bpspubs.onlinelibrary.wiley.com 
